Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.

Kyunghye Bang,Jaekyung Cheon,Jae Ho Jeong,Hyeon-Su Im,Kyu Pyo Kim,Baek-Yeol Ryoo,Changhoon Yoo

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.

2021

Kyunghye Bang
Jaekyung Cheon
Jae Ho Jeong
Hyeon-Su Im
Kyu Pyo Kim
Baek-Yeol Ryoo
Changhoon Yoo

Introduction:Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitab...

Keywords:

Internal medicine
Fluorouracil
Medicine
Liposomal Irinotecan
Oncology
Irinotecan
in patient
Metastatic Pancreatic Adenocarcinoma
previously treated
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations